YH 006
Alternative Names: YH-006Latest Information Update: 09 Jul 2025
At a glance
- Originator Beijing Biocytogen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; OX40 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in solid tumor presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 14 Apr 2023 Discontinued - Preclinical for Solid tumours in China (Parenteral) before April 2023 (Beijing Biocytogen pipeline, April 2023)
- 24 Mar 2022 YH 006 is available for licensing as of 24 Mar 2022. http://en.biocytogen.com.cn/contact-us.html